Spots Global Cancer Trial Database for Anlotinib Therapy in Patients With Advanced Lung Cancer.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Anlotinib Therapy in Patients With Advanced Lung Cancer.
Official Title: Anlotinib Hydrochloride Therapy in Patients With Advanced Lung Cancer: A Real World Study.
Study ID: NCT03940404
Conditions
Interventions
Study Description
Brief Summary: Purpose of the study: To observe the efficacy and safety of Anlotinib Hydrochloric Therapy in Patients with advanced Lung cancer in real world. Subjects of the study: advanced Lung cancer. Methods of the study: This is a real world, prospective, Non-Interventional, Follow-up registration study. Patients will get Anlotinib according to their condition and willingness. Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. After the procedure, regular follow up after every cycle. End point: Primary end point: progression-free survival (PFS). Secondary end points: overall survival (OS), disease control rate (DCR), overall response rate (ORR).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
First People's Hospital of Hangzhou, Hangzhou, Zhejiang, China
Contact Details
Name: Shenglin Ma
Affiliation: First People's Hospital of Hangzhou
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
